GSK Says Early-Stage Trial Shows Lung-Cancer Drug Benefit
GSK said an early-stage global trial of risvutatug rezetec, licensed from China's Hansoh Pharmaceutical Group, showed tumors shrank or disappeared in a majority of patients.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.